The lncRNA OGFRP1/miR-149-5p/IL-6 axis regulates prostate cancer chemoresistance

Wang, Chen; Ding, Tao; Yang, Dian; Zhang, Ping; Hu, Xiongmin; Qin, Wei; Zheng, Jianghua

doi:10.1016/j.prp.2021.153535

Cited by 15 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Ding and Liu., 2019 discovered that OGFRP1 was a risky lncRNA in LUAD, and that OGFRP1 increased the proliferation, migration, and invasion of non-small cell lung cancer through the miR-4640–5p/eIF5A axis ( Liu et al, 2021b ). Furthermore, OGFRP1 acts as an oncogene in prostate cancer ( Wang et al, 2021 ), endometrial cancer ( Lv et al, 2019 ) and gastric cancer ( Zhang et al, 2021a ). However, further work is needed to investigate the biological and molecular mechanisms of these lncRNAs.…”

Section: Discussionmentioning

confidence: 99%

Development and validation of an endoplasmic reticulum stress long non-coding RNA signature for the prognosis and immune landscape prediction of patients with lung adenocarcinoma

Zeng

Luo

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Background: Lung adenocarcinoma (LUAD), the most common histotype of lung cancer, may have variable prognosis due to molecular variations. This work investigated long non-coding RNA (lncRNA) related to endoplasmic reticulum stress (ERS) to predict the prognosis and immune landscape for LUAD patients.Methods: RNA data and clinical data from 497 LUAD patients were collected in the Cancer Genome Atlas database. Pearson correlation analysis, univariate Cox regression, least absolute shrinkage and selection operator regression analyses, as well as the Kaplan-Meier method, were used to screen for ERS-related lncRNAs associated with prognosis. The risk score model was developed using multivariate Cox analysis to separate patients into high- and low-risk groups and a nomogram was constructed and evaluated. Finally, we explore the potential functions and compared the immune landscapes of two groups. Quantitative real-time PCR was used to verify the expression of these lncRNAs.Results: Five ERS-related lncRNAs were shown to be strongly linked to patients’ prognosis. A risk score model was built by using these lncRNAs to categorize patients based on their median risk scores. For LUAD patients, the model was found to be an independent prognostic predictor (p < 0.001). The signature and clinical variables were then used to construct a nomogram. With 3-year and 5-year OS’ AUC of 0.725 and 0.740, respectively, the nomogram’s prediction performance is excellent. The 5-lncRNA signature was associated with DNA replication, epithelial-mesenchymal transition, and the pathway of cell cycle, P53 signaling. Between the two risk groups, immune responses, immune cells, and immunological checkpoints were found to be considerably different.Conclusion: Overall, our findings indicate that the 5 ERS-related lncRNA signature was an excellent prognostic indicator and helped to predict the immunotherapy response for patients with LUAD.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and validation of an endoplasmic reticulum stress long non-coding RNA signature for the prognosis and immune landscape prediction of patients with lung adenocarcinoma

Zeng

Luo

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Epigenetic processes such as DNA methylation, histone acetylation, and ncRNA interaction have been evidenced to influence the expression of genes known to be active during drug resistance mechanisms [ 192 ]. The participation of lncRNAs in chemoresistance has been extensively studied in recent years, demonstrating the existence of novel drug resistance promotors and suppressors through many different pathways [ 36 , 193 , 194 ]. For instance, the small nucleolar RNA host gene 15 (SNHG15) lncRNA was induced by Sox12 to promote chemoresistance in cervical cancer by sponging miR-4735-3p [ 195 ], whereas the colorectal neoplasia differentially expressed (CRNDE) lncRNA was found to participate in autophagy regulation, attenuating chemoresistance in gastric cancer via the SRSF6-regulated alternative splicing of the phosphatidylinositol binding clathrin assembly protein (PICALM) [ 196 ].…”

Section: Linc-ror In Drug Resistancementioning

confidence: 99%

Functional Relevance of the Long Intergenic Non-Coding RNA Regulator of Reprogramming (Linc-ROR) in Cancer Proliferation, Metastasis, and Drug Resistance

Peña-Flores

Enríquez-Espinoza

Muela-Campos

et al. 2023

ncRNA

View full text Add to dashboard Cite

Cancer is responsible for more than 10 million deaths every year. Metastasis and drug resistance lead to a poor survival rate and are a major therapeutic challenge. Substantial evidence demonstrates that an increasing number of long non-coding RNAs are dysregulated in cancer, including the long intergenic non-coding RNA, regulator of reprogramming (linc-ROR), which mostly exerts its role as an onco-lncRNA acting as a competing endogenous RNA that sequesters micro RNAs. Although the properties of linc-ROR in relation to some cancers have been reviewed in the past, active research appends evidence constantly to a better comprehension of the role of linc-ROR in different stages of cancer. Moreover, the molecular details and some recent papers have been omitted or partially reported, thus the importance of this review aimed to contribute to the up-to-date understanding of linc-ROR and its implication in cancer tumorigenesis, progression, metastasis, and chemoresistance. As the involvement of linc-ROR in cancer is elucidated, an improvement in diagnostic and prognostic tools could promote and advance in targeted and specific therapies in precision oncology.

show abstract

“…In this context, OGFRP1 is able to sequester miR-149-5p, stimulating IL-6 upregulation and promoting chemoresistance in PC tumor cells. Therefore, the OGFRP1/miR-149-5p/IL-6 axis may be a potential therapeutic target for treating chemoresistance PC cells ( 138 ).…”

Section: Cytokines and Pc Immunotherapiesmentioning

confidence: 99%

A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy

Mao

Ding

2021

Front. Oncol.

View full text Add to dashboard Cite

Prostate cancer (PC) is one of the most common malignancies among men and is the second leading cause of cancer death. PC immunotherapy has taken relatively successful steps in recent years, and these treatments are still being developed and tested. Evidence suggests that immunotherapy using cytokines as essential mediators in the immune system may help treat cancer. It has been shown that cytokines play an important role in anti-tumor defense. On the other hand, other cytokines can also favor the tumor and suppress anti-tumor responses. Moreover, the dose of cytokine in cancer cytokine-based immunotherapy, as well as the side effects of high doses, can also affect the outcomes of treatment. Cytokines can also be determinative in the outcome of other immunotherapy methods used in PC. In this review, the role of cytokines in the pathogenesis of cancer and their impacts on the main types of immunotherapies in the treatment of PC are discussed.

show abstract

The lncRNA OGFRP1/miR-149-5p/IL-6 axis regulates prostate cancer chemoresistance

Cited by 15 publications

References 28 publications

Development and validation of an endoplasmic reticulum stress long non-coding RNA signature for the prognosis and immune landscape prediction of patients with lung adenocarcinoma

Development and validation of an endoplasmic reticulum stress long non-coding RNA signature for the prognosis and immune landscape prediction of patients with lung adenocarcinoma

Functional Relevance of the Long Intergenic Non-Coding RNA Regulator of Reprogramming (Linc-ROR) in Cancer Proliferation, Metastasis, and Drug Resistance

A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy

Contact Info

Product

Resources

About